Adhoc: BioVersys AG: Bioversys announces first subjects dosed in Phase 1 clinical trial of BV100 in China
BioVersys AG / Key word(s): Study Bioversys announces first subjects dosed in Phase 1 clinical trial of BV100 in China06-Nov-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art…